Fabiana Nabarro Ferraz
Universidade Estadual de Maringá
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fabiana Nabarro Ferraz.
Homeopathy | 2011
Fabiana Nabarro Ferraz; Geysa Karla Simoni; Anélio do Nascimento; Carolina Sundin de Melo; Denise Lessa Aleixo; Mônica Lúcia Gomes; Miguel Spack; Silvana Marques de Araújo
OBJECTIVE To evaluate the effects of different forms of administration of the blood trypomastigotes biotherapy 7dH in mice experimentally infected with Trypanosoma cruzi. MATERIAL AND METHODS Male swiss mice were inoculated with 1400 blood trypomastigotes of the Y strain of T. cruzi and allocated into 5 treatment groups: IC (distilled water); TCBZ (benznidazole); TBA(7dH) (biotherapy 7dH 20 days after infection); TBB(7dH)7 (biotherapy 7dH seven days before infection); TBB(7dH)30 (biotherapy 7dH 30 days before infection). Parasitological parameters assessed included pre-patent and patent periods, parasitemia peak, total parasitemia, mortality and survival rates. Cure index was obtained by fresh blood examination, hemoculture and polymerase chain reaction (PCR). RESULTS The TBB(7dH)7 group showed a reduction in parasitemia peak, parasitemia area under the curve and total parasitemia. TBB(7dH)30 showed a tendency to increased pre-patent and survival periods, peak parasitemia was increased without increased total parasitemia. TBA(7dH) did not present significant alterations in the parasitological parameters analyzed. CONCLUSIONS Biotherapy 7dH given before infection (7 or 30 days) produces different effects suggesting modulation of the hosts immune system. The effects range from reduced parasitemia to its effective increase. The use of biotherapy to treat T. cruzi infection including dose, potency and schedule deserves further investigation.
Homeopathy | 2008
Denise Lessa Aleixo; Fabiana Nabarro Ferraz; Carolina Sundin de Melo; Mônica Lúcia Gomes; Max Jean de Ornelas Toledo; Edílson Noboyoshi Kaneshima; Ciomar Aparecida Bersani-Amado; Silvana Marques de Araújo
Chagas disease, caused by the protozoan Trypanosoma cruzi, involves immunomediated processes. Canova (CA) is a homeopathic treatment indicated in the diseases in which the immune system is depressed. This study evaluated the Random Amplification of Polymorphic DNA (RAPD) profile of T. cruzi under the influence of CA and Benznidazole (BZ). Mice infected with the genetic lineage of T. cruzi II (Y strain) were divided into 4 groups: Infected animals treated with saline solution (control group); treated with CA; treated with BZ; treated with CA and BZ combined. Treatment was given at the 5th-25th days of infection (D5-25). The parasites were isolated by haemoculture in Liver Infusion Tryptose (LIT) medium: at D5 (before treatment), D13, 15 and 25 (during treatment) and D55 and 295 (after treatment). DNA was extracted from the mass of parasites. RAPD was done with the primers lambdagt11-F, M13F-40 and L15996, the amplified products were eletrophoresed through a 4% polyacrylamide gel. Data were analyzed by the coefficient of similarity using the DNA-POP program. 163 markers were identified, 5 of them monomorphic. CA did not act against the parasites when used alone. The RAPD profiles of parasites treated with BZ and CA+BZ were different from those in the control group and in the group treated with CA. The actions of the CA and BZ were different and the action of BZ was different from the action of CA+BZ. These data suggest that CA may interact with BZ. The differences in the RAPD profile of the Y strain of T. cruzi produced by BZ, CA+BZ and the natural course of the infection suggest selection/suppression of populations.
BMC Research Notes | 2012
Denise Lessa Aleixo; Fabiana Nabarro Ferraz; Érika Cristina Ferreira; Marta de Lana; Mônica Lúcia Gomes; Benício Alves de Abreu Filho; Silvana Marques de Araújo
BackgroundThere is no published information about the use of different protocols to administer a highly diluted medication.Evaluate the effect of different protocols for treatment with biotherapic T. cruzi 17 dH (BIOTTc 17dH) on clinical/parasitological evolution of mice infected with T. cruzi-Y strain.MethodsA blind, randomized controlled trial was performed twice, using 60 28-day-old male Swiss mice infected with T. cruzi-Y strain, in five treatment groups: CI - treated with a 7% ethanol-water solution, diluted in water (10 μL/mL) ad libitum; BIOTPI - treated with BIOTTc 17dH in water (10 μL/mL) ad libitum during a period that started on the day of infection; BIOT4DI - treated with BIOTTc 17dH in water (10 μL/mL) ad libitum beginning on the 4th day of infection; BIOT4-5–6 - treated with BIOTTc 17dH by gavage (0.2 mL/ animal/day) on the 4th, 5th and 6th days after infection; BIOT7-8–9 - treated with BIOTTc 17dH by gavage (0.2 mL/ animal/day) on the 7th, 8th and 9th days after infection. We evaluated: parasitemia; total parasitemia (Ptotal); maximum peak of parasites; prepatent period (PPP) - time from infection to detection of the parasite in blood; patent period (PP) - period when the parasitemia can be detected in blood; clinical aspects; and mortality.ResultsParasitological parameters in the BIOTPI and mainly in the BIOT4PI group showed better evolution of the infection compared to the control group (CI), with lower Ptotal, lower maximum peak of parasites, higher PPP, lower PP and longer survival times. These animals showed stable body temperature and higher weight gain and water consumption, with more animals having normal-appearing fur for longer periods. In contrast, groups BIOT4-5–6 and BIOT7-8–9 showed worse evolution of the infection compared to the control group, considering both parasitological and clinical parameters. The correlation analysis combined with the other data from this study indicated that the prepatent period is the best parameter to evaluate the effect of a medication in this model.ConclusionsThe BIOT4DI group showed the best clinical and parasitological evolution, with lower parasitemia and a trend toward lower mortality and a longer survival period. The prepatent period was the best parameter to evaluate the effect of a medication in this model.
Arquivos do Instituto Biológico | 2018
Andréia Vieira Pereira; Marcelo Biondaro Góis; Tatiane Kelly Barbosa de Azevêdo; Fabiana Nabarro Ferraz; Suellen Laís Vicentino Vieira; Vanessa de Melo Cavalcanti-Dantas; Jozinete Vieira Pereira; Onaldo Guedes Rodrigues; Maria do Socorro Vieira Pereira
Arq. Inst. Biol., v.85, 1-8, e0582016, 2018 RESUMO: A associação de compostos naturais, isolados de plantas medicinais, com antibióticos convencionais, com mecanismos de ação semelhantes, torna‐se uma estratégia alternativa e viável para superar o problema da resistência. Assim, nosso objetivo foi avaliar a atividade antimicrobiana in vitro de substâncias tânicas presentes na casca de Anacardium occidentale e Anadenanthera colubrina associa‐ das à cefalexina, sobre amostras de Staphylococcus aureus. Avaliamos essa associação por meio da determinação da concentração mínima inibitória. Dessa forma, taninos e a cefalexina foram dissolvidos de forma seriada em água destilada em concentrações variando de 0,976 mg/mL a 500 mg/mL e 2 μg/mL a 512 μg/mL, respectiva‐ mente. Quando associados, inibiram o crescimento de S. aureus formando halos que variaram de 0,9 a 46 mm com concentração mínima inibitória de 7,8 mg/mL (taninos)/ 4 μg/mL (cefalexina). O efeito resultante da associação de substâncias, natural e sinté‐ tica, com mecanismos de ação semelhantes, apresentou resultados superiores aos observados quando testados isoladamente. Podemos concluir que os taninos e a cefalexina tiveram sua ação antimicro‐ biana potencializada quando utilizados em associação, permitindo o uso de uma menor concentração, mantendo seu efeito antibac‐ teriano sobre cepas de S. aureus.
Cytokine | 2017
Patrícia Flora Sandri; Angela Rigo Portocarrero; Larissa Ciupa; Fabiana Nabarro Ferraz; Gislaine Janaina Falkowski-Temporini; Willian do Nascimento da Silva Rodrigues; Érika Cristina Ferreira; Denise Lessa Aleixo; Silvana Marques de Araújo
Aim To evaluate the effects of dynamized ethyl alcohol (Ethylicum) 6cH and 30cH in mice infected with T. cruzi. Methods In a blind, randomized and controlled assay, 63 eight‐week‐old, Swiss, male mice, infected with IP (1400 trypomastigotes, T. cruzi‐Y‐strain), were allocated into groups: CNI‐non‐infected (n = 12), CI‐infected and non‐treated (n = 17), Et6cH‐infected, treated with Ethylicum 6cH (dilution 1:1012) (n = 17), Et30cH‐infected, treated with Ethylicum 30cH (dilution 1:1060) (n = 17). Treatment was administered 48 h before and after infection, followed by 56 h/56 h periods, until the 9th day after infection (a.i), for 16 h. Survival and mortality were assessed until the 82nd day after infection (a.i.). TNF‐&agr;, IL‐6, IL‐10, IL‐5 and IL‐17A cytokines were assessed in serum (3–4 animals/group), at time T0 (before infection), T8 and T12 (8th and 12th a.i), using the Mouse Cytokine 20‐Plex Panel Magnetic Kit (Invitrogen, USA). Inflammation was determined in heart sections (eosin‐hematoxylin staining) and behavior was analyzed with ANY‐maze® software. The study was approved by the Animal Ethics Committee/UEM. Statistica 8.0 and R 3.0.2 software were used for statistical analyses. Results The greater survival observed in the Et6cH group was related to decreased inflammation in heart tissue and increased IL‐5 at T0 (p < 0.05) and IL‐10 at T8 (p < 0.05), characterizing the Th2 response. It was also related to shorter periods of immobility, observed on day 12 a.i. The higher mortality in the Et30cH group was related to increased inflammation in the heart and a higher concentration of IL‐6 and TNF‐&agr; cytokines, characterizing the Th1 response. Conclusion The results demonstrate the beneficial effect of Ethylicum 6cH in acute murine infection by T. cruzi. HighlightsBeneficial effect of Ethylicum 6cH in acute murine infection by T. cruzi.Ethylicum 6cH presented pronounced Th2 response.Ethylicum 6cH decreased inflammation in heart and increased hosts survival.Ethylicum 30cH exhibited pronounced Th1 response. Graphical abstract Figure. No Caption available.
Journal of Experimental and Integrative Medicine | 2015
Denise Lessa Aleixo; Fabiana Nabarro Ferraz; Larissa Ciupa; Willian do Nascimento da Silva Rodrigues; Katiucha Rebeca Jennifer Lopes Lera; Mateus J. Benvenutti; Silvana Marques de Araújo
Objective: The aim of this study was to evaluate the effect of a biotherapeutic in very low dynamization (3dH) in murine infection by Trypanosoma cruzi. Methods: Swiss male mice (Mus musculus) infected by T. cruzi Y strain were divided into three groups according to their treatment: Control infection - 7% ethanolwater solution; 3dH each day (ED) - daily biotherapeutic T. cruzi 3dH, from the day of infection until the end of experiment; 3dH single day (SD) - biotherapeutic T. cruzi 3dH, on the day of infection for 12 h. Parasitological (total parasitemia, peak of parasites, day of the peaks, prepatent period, patent period, and survival) and clinical (body temperature and body weight) parameters were evaluated. Results: No significant differences were observed among groups for parasitological evaluation. 3dH ED group presented an earlier mortality compared to control. Clinical parameters showed that animals treated with biotherapeutic had worse outcome when compared with control animals. Conclusion: The low dynamization of T. cruzi biotherapeutic worsened its murine infection by means of clinical evaluation. Considering other studies using biotherapeutic of T. cruzi, suggests the possibility for an efficacy of different dynamizations regarding oscillatory potency-effect-curves.
SaBios-Revista de Saúde e Biologia | 2010
Erenilson Moreira Melo; Fabiana Nabarro Ferraz; Denise Lessa Aleixo
International Journal of High Dilution Research | 2014
Denise Lessa Aleixo; Leoni Villano Bonamin; Fabiana Nabarro Ferraz; Franciele Karina da Veiga; Silvana Marques de Araújo
European Journal of Integrative Medicine | 2014
Fabiana Nabarro Ferraz; Carolina Correia Bilotti; Denise Lessa Aleixo; Juliana Curi Martinichen Herrero; Anélio Dias Nascimento Júnior; Silvana Marques de Araújo
Journal of Applied Biomedicine | 2016
Fabiana Nabarro Ferraz; Franciele Karina da Veiga; Denise Lessa Aleixo; Larissa Ciupa; Benício Alves de Abreu Filho; Suelen Santos da Silva; Ivete Conchon-Costa; Wander Rogério Pavanelli; Silvana Marques de Araújo